News | April 24, 2014

Singulex’s Ultrasensitive Research Test for Cardiac Troponin-I Predicts Coronary Heart Disease

Cardiovascular risk assessment results highlighted at American Heart Association Epidemiology and Prevention Conference

Singulex Blood Test Clinical Study American Heart Association

April 24, 2014 — Singulex Inc. presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the company’s proprietary ultrasensitive Erenna Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.

“In this large prospective study utilizing Singulex’s uniquely sensitive technology, we were able to measure troponin-I in virtually every patient in the cohort,” said Wolfgang Koenig, M.D., Ph.D., FRCP, FESC, FACC, FAHA, professor of medicine/cardiology at the Department of Internal Medicine – II Cardiology at the University of Ulm Medical School, Ulm, Germany. “The results demonstrate that Singulex’s research troponin-I test can predict incident coronary heart disease in the general population which, I believe, ultimately brings greater insight into the cardiovascular risk profile of individuals who have not already been diagnosed with the disease.”

The study, led by Koenig, focused on the association between increased concentrations of cardiac troponin-I and increased risk of CHD. The population-based study was the first with significant long-term follow-up to demonstrate that modestly increased concentrations of cardiac troponin-I are linked to future CHD events.

The study was conducted in middle-aged healthy men and women without known heart disease at the time of study entry within the MONICA/KORA Augsburg studies. Serum levels of cardiac troponin-I were available in 2,745 men and women, and included 803 new cases of CHD. The average baseline concentration, or level, of cardiac troponin-I across all of the 2,745 subjects was 1.56 ng/L (1.56 pg/mL). Baseline concentrations of cardiac troponin-I were higher in CHD cases compared to non-cases (mean 2.56 vs. 1.49 ng/L, p<0.0001). After adjustment for variables of the Framingham Risk Score, the hazard ratio (HR) with 95% confidence interval (CI) for a CHD event in the top quartile (subjects with the highest cardiac troponin-I levels) compared to the bottom quartile (subjects with the lowest cardiac troponin-I values) was 2.76 (95% CI, 1.87-4.09). Thus, there was a 2.76 fold increase in risk for developing coronary heart disease in the patients with high baseline cardiac troponin-I levels compared to patients with low baseline levels. After additional adjustment for alcohol intake, physical activity and body mass index, relative risk remained essentially unchanged. Singulex’s SMC technology measured cTnI at the picogram/mL level and predicted which patients would develop CHD.

The poster, Ultrasensitive troponin-I, strongly predicts incident coronary heart disease in the general population independently of traditional risk factors. Results from the MONICA/KORA Augsburg Case-Cohort Study, by Wolfgang Koenig, M.D., et al, was presented at the 2014 American Heart Association Epidemiology and Prevention Scientific Sessions that are being held at the Hilton San Francisco Union Square in San Francisco.

For more information: www.singulex.com

 

Related Content

Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
PQ Bypass Reports Positive Results for Detour System in Patients With Long Femoropopliteal Blockages
News | Peripheral Artery Disease (PAD)| September 13, 2017
A subset analysis of the DETOUR I clinical trial showed promising safety and effectiveness results of PQ Bypass’ Detour...
Overlay Init